Pure Global
NCT06332261

Standardized Assessment in Depression Treatment in Routine Psychiatric Services

Standardized Assessment in Depression Treatment in Routine Psychiatric Services: a Retrospective Medical Record Review
Karolinska Institutet·ClinicalTrials.govRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Major Depressive Disorder
Study type
Observational
Sponsor & location
Primary sponsor
Karolinska Institutet
Location
Stockholm, Sweden
Timeline & enrollment
Phase
N/A
Start date
Mar 08, 2024
End date
Apr 01, 2024
Enrollment
4000 participants
Primary outcome

Montgomery-Åsberg Depression Rating Scale

Summary

The goal of this observational study is to evaluate current practices in depression treatment
 in psychiatric services in Stockholm, Sweden.
 
 The main questions it aims to answer are:
 
 - Are current practices consistent with local clinical guidelines in terms of standardized
 assessment and the treatments provided?
 
 - What are the present conditions for implementing measurement-based care in depression
 treatment in this setting?
 
 Data will be collected retrospectively from medical records of patients having received
 psychological or pharmacological treatment for depression from 2020 to 2023. Frequency of
 standardized assessments (not scores) using the Montgomery-Åsberg Depression Rating Scale,
 the Montgomery-Åsberg Depression Rating Scale-Self Assessment, and the Patient Health
 Questionnaire-9 is collected, together with information on patient, clinician, and treatment
 characteristics.

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06332261
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06332261 through Pure Global AI's free database. This phase not specified trial is sponsored by Karolinska Institutet and is currently Recruitment Completed. The study focuses on Major Depressive Disorder. Target enrollment is 4000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.